These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 33174519)

  • 21. EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer.
    Wang S; Tsui ST; Liu C; Song Y; Liu D
    J Hematol Oncol; 2016 Jul; 9(1):59. PubMed ID: 27448564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis, and antitumor activity evaluation of potent fourth-generation EGFR inhibitors for treatment of Osimertinib resistant non-small cell lung cancer (NSCLC).
    Zhang Y; Tong L; Yan F; Huang P; Zhu CL; Pan C
    Bioorg Chem; 2024 Jun; 147():107394. PubMed ID: 38691906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Investigation of molecular mechanism leading to gefitinib and osimertinib resistance against EGFR tyrosine kinase: molecular dynamics and binding free energy calculation.
    Singh A; Mishra A
    J Biomol Struct Dyn; 2023 Jul; 41(10):4534-4548. PubMed ID: 35510318
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer.
    Shaikh M; Shinde Y; Pawara R; Noolvi M; Surana S; Ahmad I; Patel H
    J Med Chem; 2022 Jan; 65(2):1008-1046. PubMed ID: 34323489
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In-silico evidences for binding of Glucokinase activators to EGFR C797S to overcome EGFR resistance obstacle with mutant-selective allosteric inhibition.
    Patel H; Pawara R; Surana S
    Comput Biol Chem; 2018 Jun; 74():167-189. PubMed ID: 29627693
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of a novel nitroflavone-based scaffold for designing mutant-selective EGFR tyrosine kinase inhibitors targeting T790M and C797S resistance in advanced NSCLC.
    Cristina M; Emiliano L; Leonardo S; Giulia S; Roberta G; Adolfo A; Marta SS; Paola S; Samuele R; Pierluigi S; Massimo M; Giovanna M
    Bioorg Chem; 2022 Dec; 129():106219. PubMed ID: 36308853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFR
    Park HR; Kim TM; Lee Y; Kim S; Park S; Ju YS; Kim M; Keam B; Jeon YK; Kim DW; Heo DS
    J Thorac Oncol; 2021 Nov; 16(11):1859-1871. PubMed ID: 34242789
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modification of osimertinib to discover new potent EGFR
    Xi XX; Zhao HY; Mao YZ; Xin M; Zhang SQ
    Eur J Med Chem; 2023 Dec; 261():115865. PubMed ID: 37839342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis and biological evaluation of novel osimertinib derivatives as reversible EGFR kinase inhibitors.
    Ding S; Gao Z; Hu Z; Qi R; Zheng X; Dong X; Zhang M; Shen J; Long T; Zhu Y; Tian L; Song W; Liu R; Li Y; Sun J; Duan W; Liu J; Chen Y
    Eur J Med Chem; 2022 Aug; 238():114492. PubMed ID: 35696862
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer.
    Gao X; Le X; Costa DB
    Expert Rev Anticancer Ther; 2016; 16(4):383-90. PubMed ID: 26943236
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Osimertinib, a third-generation tyrosine kinase inhibitor targeting non-small cell lung cancer with EGFR T790M mutations.
    McCoach CE; Jimeno A
    Drugs Today (Barc); 2016 Oct; 52(10):561-568. PubMed ID: 27910964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitro.
    Nishino M; Suda K; Kobayashi Y; Ohara S; Fujino T; Koga T; Chiba M; Shimoji M; Tomizawa K; Takemoto T; Mitsudomi T
    Lung Cancer; 2018 Dec; 126():149-155. PubMed ID: 30527179
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monitoring epidermal growth factor receptor C797S mutation in Japanese non-small cell lung cancer patients with serial cell-free DNA evaluation using digital droplet PCR.
    Ariyasu R; Uchibori K; Sasaki T; Tsukahara M; Kiyotani K; Yoshida R; Ono Y; Kitazono S; Ninomiya H; Ishikawa Y; Mizukami Y; Yanagitani N; Fujita N; Nishio M; Katayama R
    Cancer Sci; 2021 Jun; 112(6):2371-2380. PubMed ID: 33686722
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors.
    Wang S; Song Y; Yan F; Liu D
    Front Med; 2016 Dec; 10(4):383-388. PubMed ID: 27770386
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amivantamab (JNJ-61186372) induces clinical, biochemical, molecular, and radiographic response in a treatment-refractory NSCLC patient harboring amplified triple EGFR mutations (L858R/ T790M/G796S) in cis.
    Nagasaka M; Balmanoukian AS; Madison R; Zhang SS; Klempner SJ; Ou SI
    Lung Cancer; 2022 Feb; 164():52-55. PubMed ID: 35032819
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer.
    Lee J; Kim HS; Lee B; Kim HK; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
    Cancer; 2020 Jun; 126(11):2704-2712. PubMed ID: 32154925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural basis for the selectivity of 3rd generation EGFR inhibitors: a molecular dynamics study.
    Gad MM; Abdelwaly A; Helal MA
    J Biomol Struct Dyn; 2023; 41(13):6134-6144. PubMed ID: 35903965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance.
    Patel H; Pawara R; Ansari A; Surana S
    Eur J Med Chem; 2017 Dec; 142():32-47. PubMed ID: 28526474
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.
    Mu Y; Hao X; Xing P; Hu X; Wang Y; Li T; Zhang J; Xu Z; Li J
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2427-2433. PubMed ID: 32385709
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
    Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.